The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials.

Basel Abdelazeem Joseph Shehata Kirellos Said AbbasNahla Ahmed El-ShahatBilal MalikPramod SavarapuMostafa M EltobgyArvind Kunadi

Published in: PloS one (2022)

We concluded that ROX increased Hb level and improved iron utilization parameters in NDD-CKD patients, but ROX was associated with higher serious adverse effects, especially DVT and HTN. Our results support the use of ROX for NDD-CKD patients with anemia. However, higher-quality RCTs are still needed to ensure its safety and risk of thrombosis.

Keyphrases

chronic kidney disease
end stage renal disease
systematic review
peritoneal dialysis
ejection fraction
newly diagnosed
prognostic factors
pulmonary embolism
meta analyses
clinical trial
patient reported